spectra pharmaceutical services inc said current clinical studies its proposed dry eye drug tretinoin have not produced encouraging results based preliminary indications compnay said tests being conducted for submission food and drug administration for drug which has trade name lacramore spectra said earlier studies showing dramatic improvements isolated cases have still occurred however overall evaluation large number patients with dry eye syndrome not demonstrate consistantly beneficial results added spectra said will continue its current studies while same time undertaking review feasability proposed product spectra development stage company also said has introduced its first proprietary product hyo allergenic noniirritating cleanser for cleaning eyelids and eyelashes company said has also begun marketing line ophthalmic drugs reuter 